Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

MLL5-Driven Leukemic Transformation Is Linked to Chromatin Remodeling and Can be Targeted with ATRA in Combination with PARP1 Inhibition

Luise Araujo De Albuquerque Simoes, Isabel Weinhäuser, Diego A Pereira-Martins, Luciana Yamamoto Almeida, Vincent Van Den Boom, Fatemeh Mojallali, Dominique Sternadt, Prodromos Chatzikyriakou, Xuesen Zheng, César Alexander Ortiz Rojas, Ghulam Jeelani Mufti, Lucio Henrique Pinheiro, Lynn Quek, Gerwin A. Huls, Eduardo M. Rego, Jan Jacob Schuringa

Blood (2024) 144 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2024-209817

Published: 2024

Journal Articles

Whole Body CD8 + T Cell PET Imaging in Patients with DLBCL before and during Anti-CD19 CAR T Cell Therapy

Jaap A. van Doesum, Kylie Keijzer, Janneke W. de Boer, Nienke A.M. Smit, Adrienne H. Brouwers, Marjolijn N. Lub-de Hooge, Frank R. Pierik, Gerwin A. Huls, Lisanne V. van Dijk, Lydia Visser, Arjan Diepstra, Walter Noordzij, Simon P. Williams, Alexander Ungewickell, Sjoerd G. Elias, Elisabeth G.E. de Vries, Anne G.H. Niezink, Tom van Meerten

Blood (2024) 144 (Supplement 1): 1037.

https://doi.org/10.1182/blood-2024-199474

Published: 2024

Journal Articles

Synergistic Effect of Tamoxifen and Ruxolitinib Combination in Reducing Disease Burden in Myeloproliferative Neoplasms

Diego A Pereira-Martins, Antonio Bruno Alves-Silva, Manuela Albuquerque De Melo, Natasha Peixoto Fonseca, Isabel Weinhäuser, Fabio Augusto Bueno Perez, Artur Bernardo Ribeiro Bellomi, Lorena Lobo Figueiredo-Pontes, João Agostinho Machado-Neto, Lynn Quek, Prodromos Chatzikyriakou, Gerwin A. Huls, Emanuele Ammatuna, Jan Jacob Schuringa, Fabiola Traina

Blood (2024) 144 (Supplement 1): 4518.

https://doi.org/10.1182/blood-2024-209823

Published: 2024

Journal Articles

Cephalochromin-Induced Mitochondrial Damage Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia Models

Mariane Cristina Do Nascimento, Diego A Pereira-Martins, Guilherme Augusto Sousa Alcântara, Keli Lima, Hugo Passos Vicari, Marcelo José Pena Ferreira, Leticia Veras Costa-Lotufo, Gerwin A. Huls, Jan Jacob Schuringa, João Agostinho Machado-Neto, Eduardo Magalhães Rego

Blood (2023) 142 (Supplement 1): 5751.

https://doi.org/10.1182/blood-2023-189814

Published: 2023

Journal Articles

Reduction of Metabolic Active Tumor Volume Prior to CAR T-Cell Therapy Improves Survival Outcomes in Patients with Large B-Cell Lymphoma

Kylie Keijzer, Janneke W. de Boer, Jaap A. van Doesum, Walter Noordzij, Gerwin A. Huls, Lisanne V. van Dijk, Tom van Meerten, Anne G.H. Niezink

Blood (2023) 142 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2023-173947

Published: 2023

Journal Articles

CEBPA-Driven Expression of the Transcriptionally Inactive deltaTP73 Isoform Phenocopies TP53 mutated Poor Risk and Drug-Resistant Acute Myeloid Leukemia

Diego Pereira-Martins, César Alexander Ortiz Rojas, Isabel Weinhaeuser, Bart-Jan Wierenga, Vincent Van Den Boom, Fatemeh Mojallali, Dominique Sternadt, Thiago Mantello Bianco, Nisha van der Meer, Douglas RA Silveira, Lynn Quek, Emanuele Ammatuna, Antonio R Lucena-Araujo, Gerwin A. Huls, Eduardo Magalhães Rego, Jan Jacob Schuringa

Blood (2023) 142 (Supplement 1): 839.

https://doi.org/10.1182/blood-2023-186399

Published: 2023

Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Blood (2023) 142 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2023-173162

Published: 2023

Journal Articles

Favorable Outcome of Abbreviated R-CHOP in Patients with Primary Testicular Lymphoma

Diana Al-Sarayfi, Mirian Brink, Mar Bellido, Wouter Plattel, Gerwin A. Huls, Marcel Nijland

Blood (2023) 142 (Supplement 1): 3115.

https://doi.org/10.1182/blood-2023-186261

Published: 2023

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

Metformin-Induced Ferroptosis Is a Therapeutic Vulnerability in IDH2 -Mutant AML Linked to Metabolic Rewiring Towards Fatty Acid Oxidation

Dominique Sternadt, Diego Pereira-Martins, Douglas RA Silveira, Isabel Weinhaeuser, Ming Yang, Prodromos Chatzikyriakou, Pilar Casares Alaez, Emanuele Ammatuna, Lieve Oudejans, Gerwin A. Huls, Christian Frezza, Lynn Quek, Jan Jacob Schuringa

Blood (2023) 142 (Supplement 1): 1586.

https://doi.org/10.1182/blood-2023-188524

Published: 2023

Journal Articles

High MN1 Expression Is Associated with an Lspc-Enriched Phenotype and Glycolysis Representing a New Vulnerability in Acute Myeloid Leukemia

Diego Pereira-Martins, Noortje van Dijk, Isabel Weinhaeuser, Douglas RA Silveira, Juan Coelho Da Silva, Thiago M Bianco, César Alexander Ortiz, Fabiola Traina, Lorena L Figueiredo-Pontes, Emanuele Ammatuna, Lynn Quek, Gerwin A. Huls, Antonio R. Lucena-Araujo, Eduardo M Rego, Jan Jacob Schuringa

Blood (2022) 140 (Supplement 1): 6265–6266.

https://doi.org/10.1182/blood-2022-165151

Published: 2022

Journal Articles

Functional and Molecular Characterisation of Prospectively Isolated Subclones in Individual AML Patients Reveals Distinct Gene Regulatory Networks Linked to Targetable Metabolic Vulnerabilities

Shanna M Hogeling, Roos Houtsma, Nisha K Van Der Meer, Salam A. Assi, Paulynn Chin, Alan Cunningham, Peter Keane, Dominique Sternadt Alexandre Ramos, Lieve Oudejans, Gerwin A. Huls, Constance Bonifer, Jan Jacob Schuringa

Blood (2022) 140 (Supplement 1): 5844–5845.

https://doi.org/10.1182/blood-2022-159999

Published: 2022

Journal Articles

Targeting PIP4K2 Lipid Kinases through Thz-P1-2 Reveals Vulnerabilities Related to Mitochondrial Homeostasis and Autophagy in Acute Leukemia

Keli Lima, Diego A Pereira-Martins, Lívia Bassani Lins de Miranda, Juan L Coelho-Silva, Giovana da Silva Leandro, Isabel Weinhäuser, Rita de Cassia Cavaglieri, Wellington F Silva, Aline Medeiros Leal, Ana Paula Alencar de Lima Lange, Elvira Deolinda Rodrigues Pereira Velloso, Emmanuel Griessinger, Jacobien R Hilberink, Gerwin A. Huls, Jan Jacob Schuringa, João Agostinho Machado-Neto, Eduardo M Rego

Blood (2022) 140 (Supplement 1): 5965–5966.

https://doi.org/10.1182/blood-2022-165172

Published: 2022

Journal Articles

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Niek Van Der Maas, Kazem Nasserinejad, Thomas Pabst, Johan A. Maertens, Dimitri A. Breems, Markus G Manz, Jacqueline Cloos, Gert J. Ossenkoppele, Yngvar Floisand, Patrycja Gradowska, Bob Lowenberg, Gerwin A. Huls, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen, Jurjen Versluis

Blood (2022) 140 (Supplement 1): 127–129.

https://doi.org/10.1182/blood-2022-158137

Published: 2022

Journal Articles

Full Spectrum 40-Parameter Single-Tube Flow Cytometry Analysis for Longitudinal Immunophenotyping and Tracing of Clonal Heterogeneity in AML

Nisha K. Van Der Meer, Duy le Minh, Diego Pereira-Martins, Dimitrios Kleftogiannis, Albertus T.J. Wierenga, Kees Meijer, Andre B. Mulder, Gerwin A. Huls, Jan Jacob Schuringa

Blood (2022) 140 (Supplement 1): 9140–9141.

https://doi.org/10.1182/blood-2022-165438

Published: 2022

Journal Articles

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Blood (2022) 140 (Supplement 1): 1281–1283.

https://doi.org/10.1182/blood-2022-166544

Published: 2022

Journal Articles

Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2 -Mutant Acute Myeloid Leukemia

Dominique Sternadt, Diego Pereira-Martins, Douglas RA Silveira, Prodromos Chatzikyriakou, Maria del Pilar Casares Alaez, Isabel Weinhaeuser, Shanna M Hogeling, Emanuele Ammatuna, Gerwin A. Huls, Lynn Quek, Jan Jacob Schuringa

Blood (2022) 140 (Supplement 1): 8813–8814.

https://doi.org/10.1182/blood-2022-163282

Published: 2022

Journal Articles

M2 Macrophages Drive Resistance to Phagocytosis and Improve Mitochondrial Metabolism in Acute Myeloid Leukemia Facilitating Leukemic Transformation and In Vivo Engraftment

Isabel Weinhaeuser, Diego Pereira-Martins, Luciana Yamamoto de Almeida, Jacobien R Hilberink, Douglas RA Silveira, Lynn Quek, César Alexander Ortiz, Antonio R. Lucena-Araujo, Nienke Visser, Emanuele Ammatuna, Gerwin A. Huls, Eduardo M Rego, Jan Jacob Schuringa

Blood (2022) 140 (Supplement 1): 1259–1260.

https://doi.org/10.1182/blood-2022-165130

Published: 2022

Journal Articles

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Anthony S. Stein, Ashish Bajel, Shaun Fleming, Mojca Jongen-Lavrencic, Sylvain Garciaz, Abhishek Maiti, Nicolas Boissel, Stephane De Botton, Gerwin A. Huls, David C. de Leeuw, David Avigan, Kyle Jensen, Brigitte Demers, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, Dobrin Draganov, Giovanni Abbadessa, Andrew H Wei

Blood (2022) 140 (Supplement 1): 7476–7477.

https://doi.org/10.1182/blood-2022-166000

Published: 2022

Journal Articles

Functional Drug Screen Identifies Thiostrepton, NAMPT Inhibitors and Metformin As Potential Candidates to Target the Macrophage Tumor Microenvironment in Acute Myeloid Leukemia

Isabel Weinhaeuser, Diego Pereira-Martins, Jacobien R Hilberink, Emanuele Ammatuna, Gerwin A. Huls, Eduardo M Rego, Jan Jacob Schuringa

Blood (2022) 140 (Supplement 1): 8793–8794.

https://doi.org/10.1182/blood-2022-165115

Published: 2022

NARROW

MLL5-Driven Leukemic Transformation Is Linked to Chromatin Remodeling and Can be Targeted with ATRA in Combination with PARP1 Inhibition

Whole Body CD8 + T Cell PET Imaging in Patients with DLBCL before and during Anti-CD19 CAR T Cell Therapy

Synergistic Effect of Tamoxifen and Ruxolitinib Combination in Reducing Disease Burden in Myeloproliferative Neoplasms

Cephalochromin-Induced Mitochondrial Damage Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia Models

Reduction of Metabolic Active Tumor Volume Prior to CAR T-Cell Therapy Improves Survival Outcomes in Patients with Large B-Cell Lymphoma

CEBPA-Driven Expression of the Transcriptionally Inactive deltaTP73 Isoform Phenocopies TP53 mutated Poor Risk and Drug-Resistant Acute Myeloid Leukemia

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Favorable Outcome of Abbreviated R-CHOP in Patients with Primary Testicular Lymphoma

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Metformin-Induced Ferroptosis Is a Therapeutic Vulnerability in IDH2 -Mutant AML Linked to Metabolic Rewiring Towards Fatty Acid Oxidation

High MN1 Expression Is Associated with an Lspc-Enriched Phenotype and Glycolysis Representing a New Vulnerability in Acute Myeloid Leukemia

Functional and Molecular Characterisation of Prospectively Isolated Subclones in Individual AML Patients Reveals Distinct Gene Regulatory Networks Linked to Targetable Metabolic Vulnerabilities

Targeting PIP4K2 Lipid Kinases through Thz-P1-2 Reveals Vulnerabilities Related to Mitochondrial Homeostasis and Autophagy in Acute Leukemia

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Full Spectrum 40-Parameter Single-Tube Flow Cytometry Analysis for Longitudinal Immunophenotyping and Tracing of Clonal Heterogeneity in AML

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2 -Mutant Acute Myeloid Leukemia

M2 Macrophages Drive Resistance to Phagocytosis and Improve Mitochondrial Metabolism in Acute Myeloid Leukemia Facilitating Leukemic Transformation and In Vivo Engraftment

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Functional Drug Screen Identifies Thiostrepton, NAMPT Inhibitors and Metformin As Potential Candidates to Target the Macrophage Tumor Microenvironment in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only